ArgoMed
This article was originally published in The Gray Sheet
Executive Summary
Convertible line of credit supplied via strategic alliance with Quintiles Transnational will be used to establish a sales force for a full-scale U.S. launch of ArgoMed's Thermoflex system for benign prostatic hyperplasia, ArgoMed announces May 2. The heated water therapy system gained 510(k) clearance in August 1999, but a full-scale launch was delayed pending suitable distribution arrangements (1"The Gray Sheet" Oct. 11, 1999, p. 20). A separate agreement with Timm Medical Technologies, announced May 3, will provide exclusive North American distribution rights for direct marketing to urologists offices
You may also be interested in...
ArgoMed Seeks Partner To Distribute Low-Cost BPH Treatment Device
ArgoMed is planning to put its Thermoflex system for treatment of benign prostatic hyperplasia in the hands of a distribution partner capable of clearing a path into an already crowded market.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.